Related Experiment Video
Updated: Oct 5, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus
Faith H N Howard1, Haider Al-Janabi1, Priya Patel1
1Department of Oncology and Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK.
Abstract:
The survival strategies of infectious organisms have inspired many therapeutics over the years. Indeed the advent of oncolytic viruses (OVs) exploits the uncontrolled replication of cancer cells for production of their progeny resulting in a cancer-targeting treatment that leaves healthy cells unharmed. Their success against inaccessible tumors however, is highly variable due to inadequate tumor targeting following systemic administration. Coassembling herpes simplex virus (HSV1716) with biocompatible magnetic nanoparticles derived from magnetotactic bacteria enables tumor targeting from circulation with magnetic guidance, protects the virus against neutralizing antibodies and thereby enhances viral replication within tumors. This approach additionally enhances the intratumoral recruitment of activated immune cells, promotes antitumor immunity and immune cell death, thereby inducing tumor shrinkage and increasing survival in a syngeneic mouse model of breast cancer by 50%. Exploiting the properties of such a nanocarrier, rather than tropism of the virus, for active tumor targeting offers an exciting, novel approach for enhancing the bioavailability and treatment efficacy of tumor immunotherapies for disseminated neoplasms.
Insights
Magnetic nanoparticles enhance oncolytic virus (OV) therapy for breast cancer by improving tumor targeting and immune response, increasing survival by 50% in mice.
Area of Science:
- Oncology
- Virology
- Nanotechnology
- Immunotherapy
Background:
- Oncolytic viruses (OVs) show promise for cancer treatment by selectively replicating in cancer cells.
- Systemic administration of OVs often results in inadequate tumor targeting and reduced efficacy, especially for inaccessible tumors.
- Developing strategies to improve OV delivery and efficacy is crucial for advancing cancer immunotherapy.
Purpose of the Study:
- To investigate the potential of coassembling oncolytic herpes simplex virus type 1 (HSV1716) with magnetic nanoparticles (MNPs) for enhanced tumor targeting and therapeutic efficacy.
- To evaluate the impact of MNP-mediated delivery on viral protection against neutralizing antibodies and viral replication within tumors.
- To assess the combined effects of MNP-enhanced OV therapy on intratumoral immune cell recruitment, antitumor immunity, and tumor regression in a preclinical breast cancer model.
Main Methods:
- Herpes simplex virus type 1 (HSV1716) was coassembled with biocompatible magnetic nanoparticles derived from magnetotactic bacteria.
- The MNP-virus complex was administered systemically, and magnetic guidance was employed for tumor targeting.
- Viral biodistribution, replication, immune cell infiltration, and tumor growth were assessed in a syngeneic mouse model of breast cancer.
Main Results:
- The MNP-HSV1716 complex demonstrated improved tumor targeting and accumulation within tumors compared to the virus alone.
- The nanocarrier protected the virus from neutralizing antibodies, leading to enhanced viral replication in the tumor microenvironment.
- Treatment resulted in increased intratumoral recruitment of activated immune cells, potentiation of antitumor immunity, and significant tumor shrinkage.
- Survival in the treated group of mice increased by 50% compared to control groups.
Conclusions:
- Coassembling oncolytic viruses with magnetic nanoparticles offers a novel and effective strategy for active tumor targeting, overcoming limitations of systemic administration.
- This nanocarrier-based approach enhances the bioavailability and therapeutic efficacy of oncolytic virotherapy by improving viral delivery, protection, and immune stimulation.
- Exploiting nanocarrier properties for tumor targeting represents a promising advancement for enhancing immunotherapies against disseminated cancers.
